Tumor suppressive role of miR-569 in lung cancer

Zheng,Yi  Ping; Wu,Linxia; Gao,Jie; Wang,Yanfu

doi:10.3892/ol.2018.7869

Tumor suppressive role of miR-569 in lung cancer

Authors:
- Yi Ping Zheng
- Linxia Wu
- Jie Gao
- Yanfu Wang
View Affiliations

Affiliations: Department of Geriatrics, The First Affiliated Hospital of Dalian Medical College, Dalian, Liaoning 116000, P.R. China, Department of General Surgery, The First Affiliated Hospital of Dalian Medical College, Dalian, Liaoning 116000, P.R. China
Published online on: January 26, 2018 https://doi.org/10.3892/ol.2018.7869
Pages: 4087-4092
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNAs (miRs) are targets for genomic aberrations and emerging treatments against cancer. It has been demonstrated that targeting miR‑569 may potentially benefit patients with ovarian or breast cancer. However, the exact roles of miR‑569 remain unclear in human lung cancer cells. Using the reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), it was demonstrated that miR‑569 expression was consistently decreased in lung cancer cells. As well as cell proliferation and migration inhibition, apoptosis and cell arrest at the G1 phase were induced following reversion of miR‑569 expression in lung cancer cells. The present study demonstrated that miR‑569 was able to downregulate FOS and high mobility group A2 mRNA and protein expression using RT‑qPCR and western blot analysis. The observed role of miRNA‑569 in lung cancer cells in the present study suggested that it may be a novel and promising therapeutic target, and a novel biomarker for detecting lung cancer.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Wink KC, Roelofs E, Solberg T, Lin L, Simone CB II, Jakobi A, Richter C, Lambin P and Troost EG: Particle therapy for non-small cell lung tumors: Where do we stand? A systematic review of the literature. Front Oncol. 4:2922014. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Jemal A, Grey N, Ferlay J and Forman D: Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
4	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
5	Grose D, Morrison DS, Devereux G, Jones R, Sharma D, Selby C, Docherty K, McIntosh D, Nicolson M, McMillan DC, et al: The impact of comorbidity upon determinants of outcome in patients with lung cancer. Lung Cancer. 87:186–192. 2015. View Article : Google Scholar : PubMed/NCBI
6	Mehta A, Dobersch S, Romero-Olmedo AJ and Barreto G: Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev. 34:229–241. 2015. View Article : Google Scholar : PubMed/NCBI
7	Vasudevan S, Tong Y and Steitz JA: Switching from repression to activation: microRNAs can up-regulate translation. Science. 318:1931–1934. 2007. View Article : Google Scholar : PubMed/NCBI
8	van de Vrie M, Heymans S and Schroen B: MicroRNA involvement in immune activation during heart failure. Cardiovasc Drugs Ther. 25:161–170. 2011. View Article : Google Scholar : PubMed/NCBI
9	Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
10	Joshi P, Middleton J, Jeon YJ and Garofalo M: MicroRNAs in lung cancer. World J Methodol. 4:59–72. 2014. View Article : Google Scholar : PubMed/NCBI
11	Li F, Liu J and Li S: MicroRNA 106b ~25 cluster and gastric cancer. Surg Oncol. 22:e7–10. 2013. View Article : Google Scholar : PubMed/NCBI
12	Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, et al: Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 26:863–879. 2014. View Article : Google Scholar : PubMed/NCBI
13	Kawano O, Sasaki H, Okuda K, Yukiue H, Yokoyama T, Yano M and Fujii Y: PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer. 58:159–160. 2007. View Article : Google Scholar : PubMed/NCBI
14	Go H, Jeon YK, Park HJ, Sung SW, Seo JW and Chung DH: High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 5:305–313. 2010. View Article : Google Scholar : PubMed/NCBI
15	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
16	Qian J and Massion PP: Role of Chromosome 3q amplification in lung cancer. J Thorac Oncol. 3:212–215. 2008. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R and Resar LM: HMGA2 participates in transformation in human lung cancer. Mol Cancer Res. 6:743–750. 2008. View Article : Google Scholar : PubMed/NCBI
19	Wu Y, Song Y and Liu H: Expression and its clinical significance of HMGA2 in the patients with non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 11:377–381. 2008.(In Chinese). PubMed/NCBI
20	Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E and Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 46:503–511. 2007. View Article : Google Scholar : PubMed/NCBI
21	Volm M, Drings P and Wodrich W: Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol. 119:507–510. 1993. View Article : Google Scholar : PubMed/NCBI
22	Gartel AL and Kandel ES: miRNAs: Little known mediators of oncogenesis. Semin Cancer Biol. 18:103–110. 2008. View Article : Google Scholar : PubMed/NCBI
23	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : PubMed/NCBI
24	Garzon R and Marcucci G: Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
25	Holland AJ and Cleveland DW: Boveri revisited: Chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol. 10:478–487. 2009. View Article : Google Scholar : PubMed/NCBI
26	Yang Z, Zhuan B, Yan Y, Jiang S and Wang T: Integrated analyses of copy number variations and gene differential expression in lung squamous-cell carcinoma. Biol Res. 48:472015. View Article : Google Scholar : PubMed/NCBI
27	Wu J and Wei JJ: HMGA2 and high-grade serous ovarian carcinoma. J Mol Med (Berl). 91:1155–1165. 2013. View Article : Google Scholar : PubMed/NCBI
28	Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R and Resar LM: HMGA2 participates in transformation in human lung cancer. Mol Cancer Res. 6:743–750. 2008. View Article : Google Scholar : PubMed/NCBI
29	Wu Y, Song Y and Liu H: Expression and its clinical significance of HMGA2 in the patients with non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 11:377–381. 2008.(In Chinese). PubMed/NCBI
30	Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E and Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 46:503–511. 2007. View Article : Google Scholar : PubMed/NCBI
31	Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E and Peter ME: Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 6:2585–2590. 2007. View Article : Google Scholar : PubMed/NCBI
32	Yang Y, Zhang P, Zhao Y, Yang J, Jiang G and Fan J: Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer. Cancer Biol Ther. 17:515–525. 2016. View Article : Google Scholar : PubMed/NCBI
33	Xiang Q, Tang H, Yu J, Yin J, Yang X and Lei X: MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. Pharmazie. 68:274–281. 2013.PubMed/NCBI
34	Milde-Langosch K: The fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 41:2449–2461. 2005. View Article : Google Scholar : PubMed/NCBI
35	Chiu R, Boyle WJ, Meek J, Smeal T, Hunter T and Karin M: The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell. 54:541–552. 1988. View Article : Google Scholar : PubMed/NCBI
36	Taniguchi S, Kawano T, Mitsudomi T, Kimura G and Baba T: Fos oncogene transfer to a transformed rat fibroblast cell line enhances spontaneous lung metastasis in rat. Jpn J Cancer Res. 77:1193–1197. 1986.PubMed/NCBI